With social media receiving increased focus as the pharma industry strives to make the most of new communication technologies, we speak with Cognizant?s Bhaskar Sambasivan to find out where pharma is when it comes to social media implementation and what more should be being done.
Many pharmaceutical companies use social media platforms as channels to distribute press releases and other company announcements. Is the industry exploiting the full potential of these public platforms?
Most Internet users actively use social media. Social networks have transformed the way we communicate and, more importantly, the platform they provide is the largest, most diverse and probably the most powerful medium of communication observed to date.
For the pharmaceutical industry, social networks offer a means to bridge the gap between companies and end users. Approximately 74% of pharmaceutical companies have adopted social media platforms (1) — a number that is significantly higher than the figures for financial services and retail companies. Despite the focus on and increased uptake of social media for businesses purposes, it is only one component in a communication strategy and not a complete solution. The level of adoption and maturity in successfully implementing social media and reaping business benefits is relatively low and inadequate because of various factors. For the pharmaceutical industry, one of the main hurdles is the stringent regulatory environment.
While many pharmaceutical companies do already use platforms like Twitter and Facebook for distributing press releases and other company announcements, these channels are also being used to promote awareness of health issues and diseases, managing corporate affairs, sharing corporate social responsibility initiatives and engaging with customers while providing them with efficient service in real-time.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
2 Commerce Drive
Cranbury, NJ 08512